Scroll to Top

Volume : V, Issue : VI, July - 2015

PREVALENCE OF LEVOFLOXACIN RESISTANCE IN GRAM NEGATIVE BACILLI ISOLATES FROM CLINICAL SPECIMENS

Amol Kulkarni, S.R. Deshmukh

By : Laxmi Book Publication

Abstract :

Fluoroquinolones are one of the important classes of antibacterial agents for clinically important Gram negative bacterial pathogens. Levofloxacin is an important member of this class with highest acceptability. However, like other members it is also under threat of resistance. We have tested 122 clinical specimens of diverse genera and found a high level of resistance to levofloxacin. This observation indicates the decreased utility of this important option.

Keywords :


Article :


Cite This Article :

Amol Kulkarni, S.R. Deshmukh(2015). PREVALENCE OF LEVOFLOXACIN RESISTANCE IN GRAM NEGATIVE BACILLI ISOLATES FROM CLINICAL SPECIMENS. Indian Streams Research Journal, Vol. V, Issue. VI, http://isrj.org/UploadedData/6787.pdf

References :

  1. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  2. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  3. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  4. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  5. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  6. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  7. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  8. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  9. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  10. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  11. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  12. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  13. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  14. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  15. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  16. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  17. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  18. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  19. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  20. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  21. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  22. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  23. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  24. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  25. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  26. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  27. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  28. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  29. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  30. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  31. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  32. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  33. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  34. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  35. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  36. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  37. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  38. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  39. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  40. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  41. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  42. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  43. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  44. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  45. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  46. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  47. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  48. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  49. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  50. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  51. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  52. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  53. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  54. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  55. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  56. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  57. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  58. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  59. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  60. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  61. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  62. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  63. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  64. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  65. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  66. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  67. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  68. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  69. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  70. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  71. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  72. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  73. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  74. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  75. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  76. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  77. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  78. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  79. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  80. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  81. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  82. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  83. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  84. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  85. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  86. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  87. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  88. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  89. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  90. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  91. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  92. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  93. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  94. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  95. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  96. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  97. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  98. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  99. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  100. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  101. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  102. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  103. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  104. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  105. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  106. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  107. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  108. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  109. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  110. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  111. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  112. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  113. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  114. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  115. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  116. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  117. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  118. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  119. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  120. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  121. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  122. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  123. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  124. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  125. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  126. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  127. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  128. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  129. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  130. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  131. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  132. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  133. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  134. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  135. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  136. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  137. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  138. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  139. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  140. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  141. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  142. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  143. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  144. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  145. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  146. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  147. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  148. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  149. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  150. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  151. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  152. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  153. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  154. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  155. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  156. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  157. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  158. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  159. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  160. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  161. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  162. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  163. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  164. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  165. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  166. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  167. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  168. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  169. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  170. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  171. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  172. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  173. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  174. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  175. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  176. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  177. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  178. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  179. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  180. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  181. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  182. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  183. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  184. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  185. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  186. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  187. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  188. Hooper DC. The emerging mechanisms of Fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
  189. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  190. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  191. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  192. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  193. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  194. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  195. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  196. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  197. Drlica K, Zhao XK. DNA gyrase, topoisomerase IV and 4-quinolone. Microbiol Mol Biol Rev 1997; 61(3):377-92.
  198. Daniel F.Sahm, et al Evaluation of current activities of Fluoroquinolones against Gram-negative Bacilli using centralized in vitro testing and Electronic surveillance. Antimicrobial agents and chemotherapy, Jan 2001, p.267-274.
  199. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.
  200. Mackie and McCartney. Textbook of Practical Medical Microbiology. 14th edition; p.153, 416.
  201. Oliphant CM, Green CM: Quinolones: A comprehensive review Am Fam Physician 2002, 65: 455-464
  202. L. Drago, E. De Vecchi, B. Mombelli, L. Nicola, M. Valli and M.R. Gismondo (2001) Activity of levofloxacin and ciprofloxacin against urinary pathogens. Antimicrobial agents and Chemotherapy 48, 37-45.
  203. Clinical and Laboratory Standards Institute. Performance standards for Anti-microbial Susceptibility testing. Wayne, Pa: Eleventh Information Supplement. : 2001; Document M100-S11.

Article Post Production

    No data exists for the row/column.
Creative Commons License
Indian Streams Research Journal by Laxmi Book Publication is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://oldisrj.lbp.world/Default.aspx.
Permissions beyond the scope of this license may be available at http://oldisrj.lbp.world/Default.aspx
Copyright � 2014 Indian Streams Research Journal. All rights reserved
Looking for information? Browse our FAQs, tour our sitemap, or contact ISRJ
Read our Privacy Policy Statement and Plagairism Policy. Use of this site signifies your agreement to the Terms of Use